Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
Identification and characterization of three (3) novel fully human monoclonal antibodies, which may be used to prevent binding of IGF-I to its concomitant receptor IGFIR, consequently, modulating diseases such as cancer. More
A powerful technology for the simultaneous monitoring of protein kinase activities in cell and tissue extracts using a multiplexed electrochemical assay More
The present invention describes cytotoxic compounds with an intracellular target that can selectively enter tumor cells through specific receptors on the cell surface. More
US based researchers are seeking licensing partners for the further development of their antigen which is intended for the treatment of breast cancer but could also have applications in ovarian cancer and other malignancies. More
These cell lines (based on the widely used B16 murine melanoma cell line) were transduced with retroviral vectors encoding cDNA for either CXCR4 or CCR10 under control of a TET-dependent promoter. More
The compositions and methods of administration described in this invention are based on indole carbazole, which causes terminal differentiation of tumor cells by exploiting a normal physiologic pathway. More
The present invention concerns a stable lipid assembly comprising a biologically active lipid having a hydrophobic region and a polar headgroup. These specific lipid assemblies comprise the biologically active lipid, ceramide, a lipid derivatized... More
A method of antitumor therapy is described in which administration of a chemotherapeutic drug, encapsulated in liposomes, is supplemented by administration of an immunostimulating cytokine. The cytokine is preferably also encapsulated in liposomes.... More
Displaying 1..10 of 23 -
per page
Next page
Order by
All rights reserved. Terms and Conditions | Contact us
